Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 4/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.47 |
| ▸ | CEL | P19835 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | BRS3 | P32247 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24215061 | 0.70 | DAO (0.54) | DAOGPR84CEL | |
| SCHEMBL11395591 | 0.69 | DAO (0.42) | DAOGPR84CELHPGDBRS3 | |
| SCHEMBL8885478 | 0.69 | GPR84 (0.72) | DAOGPR84MMP1MMP9MMP12 | |
| SCHEMBL26686629 | 0.67 | DRD2 (0.59) | — | |
| SCHEMBL1733071 | 0.66 | CEL (0.51) | CEL | |
| SCHEMBL19465402 | 0.66 | BCHE (0.49) | CEL | |
| SCHEMBL8883686 | 0.66 | GPR84 (0.86) | DAOGPR84MMP1MMP9MMP12 | |
| SCHEMBL7198668 | 0.65 | DAO (0.51) | DAOGPR84CELHPGDBRS3 | |
| SCHEMBL60979 | 0.65 | CTSS (0.54) | — | |
| SCHEMBL9949704 | 0.65 | DAO (0.41) | DAOCEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0233837-A2 | Saccharide derivatives and method for their preparation | CIBA-GEIGY AG (CH) | 1987-08-26 | — | — | EP | claimed |
| US-6534528-B1 | Treatment of a leg ulcer or a decubitus ulcer, wherein the ulcer is not infected, which comprises contacting the ulcer with a pharmaceutical which comprises a powder and at least one 1-hydroxy-2-pyridone | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-18 | — | — | US | disclosed |
| EP-0879052-A1 | PREPARATIONS STIMULATING NAIL GROWTH | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-11-25 | — | — | EP | disclosed |
| WO-1997028790-A1 | PREPARATIONS STIMULATING NAIL GROWTH | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-08-14 | — | — | WO | disclosed |
| EP-0233837-A2 | Saccharide derivatives and method for their preparation | CIBA-GEIGY AG (CH) | 1987-08-26 | — | — | EP | disclosed |